Last reviewed · How we verify
WX-671
At a glance
| Generic name | WX-671 |
|---|---|
| Sponsor | Heidelberg Pharma AG |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19 (PHASE2)
- Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease (PHASE2, PHASE3)
- Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer (PHASE2)
- Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WX-671 CI brief — competitive landscape report
- WX-671 updates RSS · CI watch RSS
- Heidelberg Pharma AG portfolio CI